A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence.
Childhood cancer
Immunotherapy
Long-term follow-up
Long-term survivor
Pediatric cancer
Targeted therapy
survivorship
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
05
03
2021
received:
02
02
2021
accepted:
18
03
2021
pubmed:
17
4
2021
medline:
7
1
2022
entrez:
16
4
2021
Statut:
ppublish
Résumé
While considerable efforts and progress in our understanding of the long-term toxicities of surgery, radiation and chemotherapy in children with cancer have been made over the last 5 decades, there continues to be a wide gap in our knowledge of the long-term health impact of most novel targeted and immunotherapy agents. To address this gap, ACCELERATE, a multi-stakeholder collaboration of clinical and translational academics, regulators from the EMA and FDA, patient/family advocates and members spanning small biotechnology through to large pharmaceutical companies have initiated the development of an international long-term follow-up data registry to collect this important information prospectively. Providing critical safety data on the long-term use of these approved and investigational therapies in children will support the regulatory requirements and labeling information. It will also provide the necessary insight to help guide physicians and families on the appropriateness of a targeted or immune therapy for their child and inform survivorship planning.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29047Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National Cancer Statistics. Cancer. 2020;126(10):2225-2249.
Seibel NL, Janeway K, Allen CE, et al. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017;41(3):194-200.
Kieran MW, Geoerger B, Dunkel IJ, et al. A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors. Clin Cancer Res. 2019;25(24):7294-7302.
Pearson ADJ, Rossig C, Lesa G, et al. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020;127:52-66.
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.
Foster JH, Voss SD, Hall DC, et al. Activity of crizotinib in patients with ALK-aberrant relapsed/refractory neuroblastoma: a Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021. https://doi.org/10.1158/1078-0432.CCR-20-4224.
Leisenring WM, Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2319-2327.
Hjorth L, Haupt R, Skinner R, et al. Survivorship after childhood cancer: panCare: a European Network to promote optimal long-term care. Eur J Cancer. 2015;51(10):1203-1211.